Cantor Sees 'Clear Strategic Rationale' Behind Vertex's Buy of Crinetics — Market Talk
Vertex Pharmaceuticals' roughly $10 billion purchase of Crinetics Pharmaceuticals provides another near-term launch narrative with Palsonify, a treatment for acromegaly, Cantor analysts say in a research note. It also offers a clinically compelling program with multi-blockbuster potential in atumel…